Status:
COMPLETED
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
Lead Sponsor:
Sumitomo Pharma America, Inc.
Conditions:
Chronic Schizophrenia
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared wi...
Eligibility Criteria
Inclusion
- Entry Criteria:
- Screening for the present study will take place after subjects' participation in Study D1050233 has been completed, and after providing informed consent.
- Completed all required assessments on the final study visit in Study D1050233.
- Suitable for treatment in an outpatient setting.
Exclusion
- Any chronic organic disease of the CNS (other than schizophrenia).
- Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00789698
Start Date
December 1 2008
End Date
July 1 2011
Last Update
June 12 2015
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
K&S Professional Research Services, LLC
Little Rock, Arkansas, United States, 72201
2
Woodland International Research Group
Little Rock, Arkansas, United States, 72211
3
Comprehensive Neuroscience, Inc
Cerritos, California, United States, 90703
4
Clinical Innovations, Inc.
Costa Mesa, California, United States, 92647